Litcius/Paper detail

COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?

Gurusaravanan Kutti Sridharan, Rajesh Kotagiri, Vijay H. Chandiramani, Babu P. Mohan, Rathnamitreyee Vegunta, Radhakrishna Vegunta, Venkata Ram Pradeep Rokkam

2020American Journal of Therapeutics35 citationsDOIOpen Access PDF

Abstract

Ibuprofen is an over-the-counter medication that is used widely for the treatment of pain and fever during COVID-19 pandemic. A concern was raised regarding the safety of ibuprofen use because of its role in increasing ACE2 levels within the Renin-Angiotensin-Aldosterone system. ACE2 is the coreceptor for the entry of SARS-CoV-2 into cells, and so, a potential increased risk of contracting COVID-19 disease and/or worsening of COVID-19 infection was feared with ibuprofen use. However, available data from limited studies show administration of recombinant ACE2 improves lung damage caused by respiratory viruses, suggesting ibuprofen use may be beneficial in COVID-19 disease. At this time, there is no supporting evidence to discourage the use of ibuprofen.

Topics & Concepts

IbuprofenMedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakPandemicDiseaseRespiratory systemIntensive care medicinePharmacologyInternal medicineVirologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchPharmacological Receptor Mechanisms and Effects
COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence? | Litcius